靶向治疗中轴型脊柱关节炎：利弊与未来方向。
Treat to Target in Axial Spondyloarthritis: Pros, Cons, and Future Directions.
机构信息
Division of Rheumatology, Department of Medicine, University of Washington, 1959 Northeast Pacific Street, BB561, Seattle, WA 98195, USA. Electronic address: https://twitter.com/rheum_cat.
Section of Rheumatology, Boston University School of Medicine, 650 Albany Street, X201, Boston, MA 02119, USA.
出版信息
Rheum Dis Clin North Am. 2020 May;46(2):343-356. doi: 10.1016/j.rdc.2020.01.011.
Abstract
Treat to target describes a management paradigm that involves choosing a clinically relevant target, assessment with validated measures at a prespecified frequency, and a change in therapy if the target is not met. Although guidelines recommend treating to target in axial spondyloarthritis (axSpA), ideal methods to reach this target remain controversial. This review focuses on background for a treat-to-target strategy in axSpA. Potential targets of treatment, association of targets with outcomes, evidence of treatment impact on outcomes, and how treat to target has been incorporated into treatment guidelines are discussed. Treat-to-target trials and the research agenda for studies in axSpA are discussed.
摘要
达标治疗描述了一种管理模式，它包括选择一个具有临床相关性的目标，用经过验证的测量方法在预先指定的时间间隔进行评估，如果目标未达到，则改变治疗方法。尽管指南建议在中轴型脊柱关节炎（axSpA）中进行达标治疗，但实现这一目标的理想方法仍存在争议。这篇综述重点介绍了 axSpA 达标治疗策略的背景。讨论了潜在的治疗靶点、靶点与结局的关联、治疗对结局的影响证据，以及如何将达标治疗纳入治疗指南。还讨论了达标治疗试验和 axSpA 研究议程。
相似文献
1
Treat to Target in Axial Spondyloarthritis: Pros, Cons, and Future Directions.靶向治疗中轴型脊柱关节炎：利弊与未来方向。
Rheum Dis Clin North Am. 2020 May;46(2):343-356. doi: 10.1016/j.rdc.2020.01.011.
2
Treat to Target in Axial Spondyloarthritis.靶向治疗在中轴型脊柱关节炎中的应用。
Rheum Dis Clin North Am. 2019 Nov;45(4):519-535. doi: 10.1016/j.rdc.2019.07.003. Epub 2019 Aug 17.
3
Recent advances in managing axial spondyloarthritis.轴性脊柱关节炎治疗的最新进展
F1000Res. 2020 Jul 13;9. doi: 10.12688/f1000research.22577.1. eCollection 2020.
4
Are patient-reported outcome instruments for ankylosing spondylitis fit for purpose for the axial spondyloarthritis patient? A qualitative and psychometric analysis.强直性脊柱炎患者报告结局工具是否适用于中轴型脊柱关节炎患者？一项定性和心理测量学分析。
Rheumatology (Oxford). 2015 Oct;54(10):1842-51. doi: 10.1093/rheumatology/kev125. Epub 2015 May 21.
5
[Treat-to-target (T2T) recommendation for patients with spondyloarthritis - translation into German].[脊柱关节炎患者的治疗达标（T2T）建议 - 德语翻译]
Z Rheumatol. 2016 Nov;75(9):903-909. doi: 10.1007/s00393-016-0124-0.
6
How to Monitor Disease Activity of Axial Spondyloarthritis in Clinical Practice.如何在临床实践中监测中轴型脊柱关节炎的疾病活动度。
Curr Rheumatol Rep. 2024 May;26(5):170-177. doi: 10.1007/s11926-024-01141-0. Epub 2024 Feb 19.
7
Axial Spondyloarthritis in the Chiropractic Care Setting: A Systematic Literature Review.整脊治疗环境中的中轴型脊柱关节炎：系统文献回顾。
J Clin Rheumatol. 2022 Mar 1;28(2):e589-e595. doi: 10.1097/RHU.0000000000001776.
8
Treat to Target in Axial Spondyloarthritis: What Are the Issues?中轴型脊柱关节炎的治疗达标：存在哪些问题？
Curr Rheumatol Rep. 2017 May;19(5):22. doi: 10.1007/s11926-017-0648-6.
9
Consensus statement on the investigation and management of non-radiographic axial spondyloarthritis (nr-axSpA).关于非放射学中轴型脊柱关节炎（nr-axSpA）调查与管理的共识声明。
Int J Rheum Dis. 2014 Jun;17(5):548-56. doi: 10.1111/1756-185X.12358. Epub 2014 Mar 28.
10
Clinical practice recommendations for the use of imaging in the diagnosis and management of axial spondyloarthritis in Taiwan.台湾影像学诊断和管理中轴型脊柱关节炎的临床实践推荐
Int J Rheum Dis. 2020 Jan;23(1):24-36. doi: 10.1111/1756-185X.13679. Epub 2019 Dec 13.
引用本文的文献
1
Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study.在 GO-ALIVE 研究中，经过一年的治疗，静脉注射戈利木单抗治疗早、晚期强直性脊柱炎的疗效和安全性。
J Clin Rheumatol. 2022 Aug 1;28(5):270-277. doi: 10.1097/RHU.0000000000001853. Epub 2022 Jun 1.
2
Early Improvements in Disease Activity Indices Predict Long-Term Clinical Remission Suggested by the Treat-to-Target Strategy in Patients with Ankylosing Spondylitis Receiving TNF-α Inhibitor Treatment.强直性脊柱炎患者接受肿瘤坏死因子-α抑制剂治疗时，疾病活动指数的早期改善预示着达标治疗策略所提示的长期临床缓解。
J Clin Med. 2021 Sep 21;10(18):4279. doi: 10.3390/jcm10184279.
3
Factors associated with remission at 5-year follow-up in recent-onset axial spondyloarthritis: results from the DESIR cohort.与近期发病的中轴型脊柱关节炎患者在 5 年随访时缓解相关的因素：来自 DESIR 队列的研究结果。
Rheumatology (Oxford). 2022 Apr 11;61(4):1487-1495. doi: 10.1093/rheumatology/keab565.
本文引用的文献
1
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.2019 年美国风湿病学会/脊柱关节炎协会/脊柱关节炎研究和治疗网络关于治疗强直性脊柱炎和非放射学中轴型脊柱关节炎的建议更新。
Arthritis Rheumatol. 2019 Oct;71(10):1599-1613. doi: 10.1002/art.41042. Epub 2019 Aug 22.
2
The Effect of TNF Inhibition on Bone Density and Fracture Risk and of IL17 Inhibition on Radiographic Progression and Bone Density in Patients with Axial Spondyloarthritis: a Systematic Literature Review.TNF 抑制剂对骨密度和骨折风险的影响，以及 IL17 抑制剂对轴性脊柱关节炎患者影像学进展和骨密度的影响：系统文献回顾。
Curr Rheumatol Rep. 2019 Mar 12;21(5):20. doi: 10.1007/s11926-019-0818-9.
3
Treat-to-target in rheumatoid arthritis - are we there yet?类风湿关节炎的达标治疗——我们做到了吗？
Nat Rev Rheumatol. 2019 Mar;15(3):180-186. doi: 10.1038/s41584-019-0170-5.
4
Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study.司库奇尤单抗治疗强直性脊柱炎的疗效持久且结构进展低：MEASURE 1 研究的 4 年结果。
Rheumatology (Oxford). 2019 May 1;58(5):859-868. doi: 10.1093/rheumatology/key375.
5
Introduction: .引言：.
Diabetes Care. 2019 Jan;42(Suppl 1):S1-S2. doi: 10.2337/dc19-Sint01.
6
Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.特稿：2018 年美国风湿病学会/国家银屑病基金会银屑病关节炎治疗指南。
Arthritis Rheumatol. 2019 Jan;71(1):5-32. doi: 10.1002/art.40726. Epub 2018 Nov 30.
7
Spinal Radiographic Progression in Early Axial Spondyloarthritis: Five-Year Results From the DESIR Cohort.早期中轴型脊柱关节炎的脊柱放射学进展：来自 DESIR 队列的 5 年结果。
Arthritis Care Res (Hoboken). 2019 Dec;71(12):1678-1684. doi: 10.1002/acr.23796. Epub 2019 Nov 14.
8
Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry.强直性脊柱炎患者停用肿瘤坏死因子抑制剂：一项基于美国Corrona注册中心的观察性研究
Rheumatol Ther. 2018 Dec;5(2):537-550. doi: 10.1007/s40744-018-0129-z. Epub 2018 Oct 23.
9
Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study.生物制剂与炎症性关节炎心血管事件：一项前瞻性全国队列研究。
Arthritis Res Ther. 2018 Aug 7;20(1):171. doi: 10.1186/s13075-018-1669-x.
10
Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis.ASAS 健康指数的测量特性：一项在患有中轴型和外周型脊柱关节炎患者中的全球研究结果。
Ann Rheum Dis. 2018 Sep;77(9):1311-1317. doi: 10.1136/annrheumdis-2017-212076. Epub 2018 Jun 1.
Zotero 插件